Is it just me or is the stock market boring as a Knicks game these days? I just can't get excited. I blame the quants and the program traders, the market has an unnatural hitch to it now pulled along by Index fund trading, xta large capitalized stocks and the buying back of shares to conceal rather average income growth.
Perhaps it's just hard to find buys at a high but the pickings are not great now I don't think. One stock I like very much is Zeltiq. Healthcare is a great place to be stock wise and ZLTQ occupies a neat niche somewhere between heath and tech.
ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis.
It's all about the apoptosis stupid! I've been watching this stock for a few years basically waiting for 60 minutes to do a piece about " Cold Fraud & Fat " but such a piece has not come and the earnings numbers continue to depict a flourishing company.
Zeltiq reports preliminary revenues and provides outlook for 2015
Jan 13 2015, Zeltiq (NASDAQ:ZLTQ) expects Q4 and full-year revenues of $51M - 52M (+44%) and $175M - 176M (+57%), respectively.
Ok this is a company growing at quite a good clip-- one freezing fat here in the states we don't need to worry about the strong dollar .
Event: 27th Annual ROTH Conference
Date: Monday, March 9, 2015
Time: 10:30 a.m. PT / 1:30 p.m. ET
Event: Barclays Global Healthcare Conference
Date: Thursday, March 12, 2015
Time: 10:15 a.m. ET / 7:15 a.m. PT
This is what the company says:
WHY THE COOLSCULPTING PROCEDURE IS DIFFERENT
The CoolSculpting procedure using Cryolipolysis® is fundamentally different from other non- or minimally invasive modalities. Other methods of fat removal primarily involve necrotic cell death by damaging fat with heat, high-intensity focused ultrasound, or chemical injections. Each approach poses potential technical challenges, particularly with respect to targeting the right tissue depth and unintended damage to other structures close to or within the fat layer. Predictability of efficacy using these other techniques is also uncertain. In contrast, the CoolSculpting procedure using Cryolipolysis® induces apoptosis only in fat cells to gently and gradually reduce the fat layer while preserving all other tissue.
You may be surprised to find ZLTQ is up 27% in 3 months. It's not a stock you hear about much but it's quietly marching up. This is a powerful chart pattern (just now flagging) and a company with the earnings potential to keep the rally going. My bet is these two earnings conferences coming up next week boost the stock into the low to mid $40's. From there I believe Zeltiq can make you some real money. It is a top idea for me, end of year target. $65.00.
ZLTQ- $33.50 Buy. ~stoney
Next Up:
Expeditors International of Washington Inc. (EXPD).
Perhaps it's just hard to find buys at a high but the pickings are not great now I don't think. One stock I like very much is Zeltiq. Healthcare is a great place to be stock wise and ZLTQ occupies a neat niche somewhere between heath and tech.
ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis.
It's all about the apoptosis stupid! I've been watching this stock for a few years basically waiting for 60 minutes to do a piece about " Cold Fraud & Fat " but such a piece has not come and the earnings numbers continue to depict a flourishing company.
Zeltiq reports preliminary revenues and provides outlook for 2015
Jan 13 2015, Zeltiq (NASDAQ:ZLTQ) expects Q4 and full-year revenues of $51M - 52M (+44%) and $175M - 176M (+57%), respectively.
Ok this is a company growing at quite a good clip-- one freezing fat here in the states we don't need to worry about the strong dollar .
Event: 27th Annual ROTH Conference
Date: Monday, March 9, 2015
Time: 10:30 a.m. PT / 1:30 p.m. ET
Event: Barclays Global Healthcare Conference
Date: Thursday, March 12, 2015
Time: 10:15 a.m. ET / 7:15 a.m. PT
This is what the company says:
WHY THE COOLSCULPTING PROCEDURE IS DIFFERENT
The CoolSculpting procedure using Cryolipolysis® is fundamentally different from other non- or minimally invasive modalities. Other methods of fat removal primarily involve necrotic cell death by damaging fat with heat, high-intensity focused ultrasound, or chemical injections. Each approach poses potential technical challenges, particularly with respect to targeting the right tissue depth and unintended damage to other structures close to or within the fat layer. Predictability of efficacy using these other techniques is also uncertain. In contrast, the CoolSculpting procedure using Cryolipolysis® induces apoptosis only in fat cells to gently and gradually reduce the fat layer while preserving all other tissue.
You may be surprised to find ZLTQ is up 27% in 3 months. It's not a stock you hear about much but it's quietly marching up. This is a powerful chart pattern (just now flagging) and a company with the earnings potential to keep the rally going. My bet is these two earnings conferences coming up next week boost the stock into the low to mid $40's. From there I believe Zeltiq can make you some real money. It is a top idea for me, end of year target. $65.00.
ZLTQ- $33.50 Buy. ~stoney
Next Up:
Expeditors International of Washington Inc. (EXPD).